Amgen and Micromet Inc. Jan. 26 announced that they have entered into a definitive merger agreement under which Amgen will acquire Micromet for approximately $1.16 billion.
Micromet is a biotechnology company founded in Germany with its research and development center in Munich and headquarters in Rockville, Md., the companies said. Amgen is based in Thousand Oaks, Calif.
The transaction was unanimously approved by both the Amgen and Micromet boards of directors, the companies said.
The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in phase II clinical development for acute lymphoblastic leukemia, the companies said. Blinatumomab also is ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.